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A B S T R A C T
It is unclear if endometrial cancer (EC) patients are aware of their modifiable risk factors. We administered a 33-
item questionnaire to EC patients at a university-based cancer center to assess their understanding of how co-
morbidities and lifestyle/sexual behaviors impact their cancer risk. We also inquired about their access to a
primary care physician (PCP). Pearson's χ2 test or Fisher's exact test were used to assess differences in under-
standing based on a dichotomized Charlson comorbidity score,< 7 vs ≥7. Of the 50 surveyed women (81%
response rate), 39 reported hypertension (80%) and 36 (72%) diabetes. All had a PCP. Most were aware that
obesity contributes to diabetes (43/48, 90%), hypertension (42/48, 88%), and heart attack (42, 88%), but only
19/49 (39%) knew that EC is more common in overweight/obese women. More than half lacked understanding
of the following risks including modifiable risk factors–unhealthy diet (31, 62%), hormone replacement therapy
(38, 76%), alcohol (30, 60%), and the protective effects of cigarette smoking (38, 76%). Most also incorrectly
identified the following sexual health factors as risks for EC: early coitarche (30, 60%), or having an abortion
(27, 54%), a sexually transmitted infection (35, 70%) or human immunodeficiency virus (34, 68%). Although EC
patients recognize that obesity is linked to comorbidities, less than half are aware that it contributes to their
cancer risk. Furthermore, responses to lifestyle/sexual health behaviors suggest women may lack understanding
of global differences between endometrial and cervical cancer risk factors.
1. Introduction
More than 50% of women with early stage endometrial cancer (EC)
die from intercurrent illnesses rather than cancer itself (Binder et al.,
2016). Obesity has been shown repeatedly to be one of the strongest EC
risk factors that drives all-cause and cancer-specific mortality
(Gunderson et al., 2014; Arem et al., 2013; von Gruenigen et al., 2006).
Appropriately, an abundance of research has been dedicated to better
understanding patients' knowledge of the impact of obesity on cancer,
and multi-centered weight loss interventions have been implemented
among EC survivors to help reduce their risk of death (Ackermann
et al., 2005; Connor et al., 2017; Haggerty et al., 2017a,b; Kuroki et al.,
2015; Soliman et al., 2008). Unfortunately, positive outcomes of weight
loss interventions are brief and reach only a small subset of women
affected with EC (Haggerty et al., 2017a).
Less publicized, although equally important, are the impact of other
obesity-related comorbidities such as diabetes and hypertension, which
have been associated with EC progression and decreased survival even
after adjusting for stage and grade (Nagle et al., 2018; Modesitt et al.,
2006). A multidisciplinary approach to cancer care and survivorship
needs to address not only cancer-specific risks [eg, unopposed estrogen,
hormone replacement therapy (HRT), tamoxifen exposure, family his-
tory, etc], but also obesity-related comorbidities. Therefore, we im-
plemented a survey to evaluate patient understanding of how co-
morbidities and lifestyle/sexual behaviors impact their cancer risk. Our
secondary objective was to assess what proportion of EC patients have a
primary care physician and if not, whether they felt a referral to an
internal medicine physician was acceptable. Due to the lack of a stan-
dardized knowledge assessment tool for cancer risk, to address these
objectives, we conducted a pilot survey study among EC patients
treated at a National Cancer Institute (NCI) designated comprehensive
cancer center.
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We performed a single institution survey study of 50 women with
active or treated EC from February 13, 2019 to April 8, 2019. A total of
62 patients were approached to complete the study; 12 patients de-
clined to participate or withdrew from the study at a later time. All
procedures were reviewed and approved by Washington University's
Human Research Protection Office (HRPO ID# 201901044). We in-
cluded women at least 18 years of age who were able to read and write
English and provide signed informed consent. Cancer diagnosis was
confirmed by review of pathology reports. All patients were included
regardless of histologic type, stage, current management, or disease
status (in remission, stable, progressive, and/or recurrent). Exclusion
criteria were as follows: patients under the age of 18 years, patients
without a diagnosis of endometrial cancer, and patients unable to read
or write English.
All patients invited to participate were under the care of faculty
members of the Division of Gynecologic Oncology at Washington
University School of Medicine and Siteman Cancer Center, an NCI de-
signated comprehensive cancer center. Clinic schedules were screened
to identify eligible patients and a research team member approached
those who met eligibility criteria during their outpatient appointment.
Patients were assured that study participation was voluntary, con-
fidential, and had no impact on their care. They completed a 33-item
questionnaire (Supplemental Figure) at the time of their appointment.
The estimated time for survey completion was approximately
10–15mins, and there was no required follow-up.
The primary outcome was the proportion of EC patients who cor-
rectly identified that obesity is a risk factor for EC. This was assessed
using a composite of two questions with answer choices: True/False/I
don't know: 1) Endometrial cancer is more common in overweight or
obese people and 2) Weighing too much makes a woman more likely to
have endometrial cancer. Questions assessed patients' knowledge of the
association between obesity, comorbidities, lifestyle and sexual health
behaviors and EC risk. Each question had one correct answer, either
true or false; “not sure” was an available answer choice for each
knowledge question. Questions specifically related to obesity were
modified from a previously published survey study on obesity-related
risk factors (Kuroki et al., 2015). Those regarding sexual health and
other risk factors (eg, hormone replacement therapy, family history, the
role of Pap tests etc) were based on a prior survey that highlighted
patients' lack of knowledge regarding differences between cervical and
EC risks (Ackermann et al., 2005).
Patients were asked about their sociodemographic information in-
cluding age, race, yearly income, highest level of education, and history
of alcohol, cigarette or recreational drug use. These were constructed
from validated items in the Center of Disease Control Behavioral Risk
Factor Surveillance System surveys (Centers for Disease Control and
Prevention, 2018). Other clinical data were abstracted from patient's
electronic medical records included age, body mass index (BMI), cancer
stage, treatment, and past medical history which was used to calculate a
Charlson Comorbidity Index Score (Charlson et al., 1987) for each re-
spondent.
Demographic information was summarized with descriptive statis-
tics. Continuous measurements were summarized with means, standard
deviations, medians, percentile, and ranges. Bivariate analysis was
conducted using Pearson's χ2 or Fisher's exact tests where appropriate
for categorical variables, and Mann-Whitney U for non-parametric
continuous variables. All calculations were performed using SAS ver-
sion 9.4 (SAS Institute, Cary, NC) and associations were considered
Table 1
Patient demographics and clinical characteristics (N=50).
Characteristics N=50
Age, yeara 67 (59,74)
Time from diagnosis (months) 19 (9, 53)





High school or less 18 (36)







< $20,000 7 (14)
$20,000 to $49,999 14 (28)




Never married 5 (10)
Married 25 (50)
Separated, divorced, or single 10 (20)
Widowed 9 (18)
Prefer not to say 1 (2)
Nulliparity 6 (12)
Prior hormone replacement therapy 9 (18)
Alcohol consumption per week
None 35 (70)
Occasionally 9 (18)







Mean systolic blood pressureb 139 (126, 151)






Not at all 23 (46)
A couple times a month 7 (14)
Once a week 7 (14)
More than once a week 13 (26)
# of patients who reported a weight gain in last year 10 (20)
# of patients who reported a weight loss in the last year 18 (36)
Recent weight gainc 9.5 (7,10)
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statistically significant if p < .05.
3. Results
Of the 62 EC patients approached to participate, 50 (81%) com-
pleted the survey, and their demographic and clinical information is
displayed in Table 1. Median age was 67 years, and the majority were
white (42, 84%), educated with a college degree or higher (32, 64%)
and diagnosed with a Stage I-II (39, 78%), endometrioid adenocarci-
noma (37, 74%). Eighteen percent had been diagnosed with recurrence
and 70% were not undergoing any treatment. Twenty-five (50%) had a
Charlson Comorbidity index score of ≥7, 40 (80%) had hypertension,
and 14 (28%) had diabetes. Median body mass index was 37 kg/m2, 44
(88%) correctly identified themselves as overweight or obese, and 23
(46%) reported no engagement in exercise. Eighteen (36%) reported a
median weight loss of approximately 17.5 pounds (interquartile range,
IQR 10, 35) over the last year. Of the 10 (20%) women who reported
weight gain within the last year, the median number of pounds gained
was 9.5/year (IQR 7, 10). All patients (50, 100%) had a primary care
provider that they followed with regularly.
Assessment of patient knowledge regarding risk factors is shown in
Table 2. Most patients were aware that obesity is a risk factor for dia-
betes (43, 90%), hypertension (42, 88%), and heart attack (42, 88%),
but more than half lacked understanding that EC is more common in
overweight or obese people (31, 62%). There were no differences in
knowledge when respondents were stratified by BMI (data not shown)
or Charlson comorbidity score.
Other questions regarding modifiable risk factors that were in-
correctly answered or marked unsure by> 50% of respondents in-
cluded the following: unhealthy diet (31, 62%), hormone replacement
therapy (38, 76%), and social health behaviors such as alcohol (30,
60%), illegal drugs (26, 52%), and cigarette smoking (38, 76%).
Responses to questions regarding sexual and gynecologic health are
shown in Table 2. Twenty-seven women (54%) believed that not getting
a Pap test increased their risk for EC. The majority incorrectly identified
or were unsure if having sex early in life (30, 60%), having an abortion
(27, 54%), having a sexually transmitted disease (35, 70%), and human
immunodeficiency virus (34, 68%) were risk factors for EC.
4. Discussion
Women with EC are susceptible to public health messages about the
health risks of obesity, yet they remain naïve about their EC-specific
risks. While a majority of respondents understood the link between
obesity and diabetes, hypertension, and heart attack, less than half
identified the association between obesity and EC. The finding that
most EC patients were obese despite this level of understanding of the
harmful effects of obesity suggests that there is limited public knowl-
edge regarding the link between obesity and endometrial cancer. This
infers that educational messages about the link between EC and obesity
Table 1 (continued)
Characteristics N=50
No evidence of disease 32 (64)
Alive with disease 18 (36)
a Reported as median (Interquartile range).
b Median (Interquartile range) systolic and diastolic blood pressure among
the 40 patients who had a diagnosis of hypertension. All were on anti-
hypertensive medications.
c Among those women who reported a weight gain/loss in the last year.
Reported as median (Interquartile range).
d Missing data Employment status (n=1) Annual income (n=4).
Table 2
Patient knowledge assessment of risk factors for endometrial cancer.
Survey questions Missing data n Incorrect answer/Unsure n
(%)
CCI score < 7 N=25 CCI score≥ 7 N=25
Obesity-related questionsa
Endometrial cancer is more common in overweight or obese people. 1 31 (62) 16 (64) 15 (60)
Weighing too much makes a woman more likely to have endometrial
cancer.
1 26 (52) 11 (44) 15 (60)
Comorbidity questionsa
Obesity or being overweight leads to other health problems such as:
Diabetes 2 5 (10) - -
High blood pressure 2 6 (12) 3 (12) 3 (12)
Heart attacks 2 6 (12) 2 (8) 4 (16)
Social history questionsa
What makes a woman more likely to have endometrial cancer?
Drinking too much alcohol 2 30 (60) 14 (56) 16 (64)
Using illegal drugs 1 26 (52) 14 (56) 12 (48)
Cigarette smoking 2 38 (76) 19 (76) 19 (76)
Sexual health questionsa
Endometrial cancer is a sexually transmitted disease.
What makes a woman more likely to have endometrial cancer? 0 4 (8) 2 (8) 2 (48)
Having sex early in life 1 30 (60) 16 (64) 14 (56)
Having sex without a condom 1 22 (44) 14 (56) 8 (32)
Having multiple sex partners 1 24 (48) 13 (52) 11 (44)
Oral sex 2 21 (42) 11 (44) 10 (40)
Having an abortion 2 27 (54) 14 (56) 13 (52)
Having a sexually transmitted infection 1 35 (70) 17 (68) 18 (72)
HIV (human immunodeficiency virus) 1 34 (68) 16 (64) 18 (72)
Miscellaneous questionsa
What makes a woman more likely to have endometrial cancer?
Others in the family have it 2 23 (46) 9 (36) 14 (56)
Not getting a Pap test done 1 27 (54) 12 (48) 15 (60)
Unhealthy diet (i.e. fast-food, little fresh vegetables, fruit) 1 31 (62) 13 (52) 18 (72)
Hormone replacement therapy 1 38 (76) 16 (64) 22 (88)
CCI: Charlson Comorbidty Index.
Data are frequencies (%), p-value based on χ2/Fisher's exact test.
a Answer choices were dichotomized as true versus false/not sure.
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may be insufficient to motivate behavior change. Furthermore, women
commonly misclassified lifestyle and sexual behaviors that are strongly
linked to cervical cancer as EC risks, highlighting a more global mis-
understanding of risks associated with preventable gynecologic cancers.
Publications over the last decade reflect that women's knowledge of
EC risks have not improved over time, though they may have more
accurate self-perception of their weight. Prior work from 2008 showed
that 42% of women in the general population without a diagnosis of
cancer were aware that obesity increases the risk of EC (Soliman et al.,
2008). In 2012, a telephone survey of 1433 adults, both female and
male, in Australia, reported public knowledge and beliefs regarding
behavioral risk factors for cancer. Mirroring similar patterns of
knowledge to our study of U.S. women with EC, they reported only 18%
were aware that obesity increased the risk of EC, while the majority
were aware of the attributable risk of obesity on diabetes (79%), hy-
pertension (74%) and heart disease (73%). In 2017, Connor et al. not
only showed that the obese, EC patients commonly misclassified their
weight, but that 44% knew obesity was a risk factor for their cancer
type, and only 38% had discussed their weight with their oncologist
(Connor et al., 2017). That same year, our institution participated in a
Transdisciplinary Research in Energetics and Cancer (TREC) initiative
and was one of 3 academic medical centers to conduct a multi-site
randomized study of 196 obese, EC survivors (Haggerty et al., 2017a).
Participants completed knowledge assessments of obesity as a risk for
EC and interest in weight management; and 41 patients were rando-
mized to a 6-month intervention of telemedicine with Wi-Fi scales
(n=14), text messaging (n= 13), or enhanced usual care (n=15).
They showed a third of survey participants lacked awareness that
obesity increased the risk of EC, and 40% misclassified their body mass.
Importantly though, the TREC study showed that technology-based
lifestyle interventions were accessible and resulted in weight loss and
improved quality of life.
Two years later, our current study showed improved self-awareness
of obesity and enhanced knowledge about the associated risk of obesity
on EC. Unfortunately, most patients were not actively losing weight,
and in fact, 20% reported gaining almost 10 pounds during the pre-
ceding year, but 36% reported having lost a median of 17.5 pounds.
While most remained obese, this suggests that some women are
amenable to lifestyle modification. Further research is needed to ex-
plore what motivates these women, what strategies they employed for
successful weight loss, and whether those strategies can motivate suc-
cessful weight loss in others. Given that the overwhelming majority of
early stage endometrioid adenocarcinoma patients are cured of their
cancer and instead die from intercurrent illnesses (Binder et al., 2016),
the focus of weight loss counseling in this obese population should be
on reducing preventable premature death from cardiovascular disease
and diabetes.
Our study is limited by the inherent biases of any survey study,
including potential for selection and recall bias. We acknowledge our
sample size is small and not restricted to endometrioid histology, but
given the consistency of our findings with the current literature, it is
unlikely that our findings would significantly change with a larger
sample of women with Type I EC. Our findings reinforce prior evidence
to highlight the need for intervention trials that test innovative strate-
gies to modify behaviors to reduce obesity. Third, these data were
collected at a single academic institution, thus limiting generalizability.
Collection during office visits for ongoing cancer care posed risks for
incorrect answers due to potential time constraints and distractions;
nonetheless, all questions allowed for respondents to mark, “I don't
know” to minimize skipped questions, and at most, there were 3
missing responses per any one knowledge question (Table 2).
In conclusion our study showed that women with EC lacked fun-
damental knowledge of their cancer risk factors. Most striking is the
discrepancy in knowledge related to the risk of obesity on comorbidities
versus EC; however, response to lifestyle/sexual health behaviors sug-
gest women may be unaware of global differences between endometrial
and cervical cancer risk factors. A national campaign to decrease the
prevalence of these preventable gynecologic cancers is long overdue;
and the priority should be on weight loss and human papilloma virus
vaccination, respectively. More advocacy by medical professional so-
cieties to promote a culture change and weight loss are needed. Among
our subspecialty, the Society of Gynecologic Oncology (SGO) has an
obesity webpage which includes a toolkit to facilitate discussions about
weight management as well as links to clinical trials of exercise, diet
and nutrition as well as a BMI calculator. The National Comprehensive
Cancer Network guidelines set forth recommendations for EC surveil-
lance exams to include obesity and nutrition counseling. Lastly, the NCI
has charged oncologists and primary care providers with the task of
engaging in multidisciplinary, survivorship cancer care to address in-
tercurrent illnesses as well as provide appropriate surveillance for
cancer recurrence and late side effects of treatment (Hewitt et al.,
2006). Supported by our survey results, it would be imperative for fu-
ture research efforts to involve both PCP and oncologists to not only
enhance awareness of preventable cancers, but also evaluate different
models of survivorship care for EC patients to incorporate effective
education and counseling regarding their modifiable risk factors in
order to improve clinical outcomes.
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